Associated Papers
Stoichiometric transport of estrone 3-sulfate among genetic variants of OATP1A2 and OATP2B1 and structural analysis by molecular dynamics simulation: Impairment of gating mechanism in the unstable inward-open conformation of OATP2B1 (Asp215Val) significantly suppress the transport activity.
Akiyoshi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
In vitro characterization of SLCO2B1 genetic variants.
Sinokki A et al.
Journal of Pharmaceutical Sciences, 2025
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics.
Jang JH et al.
Journal of Pharmaceutical Analysis, 2023
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
Lehtisalo M et al.
British Journal of Clinical Pharmacology, 2023
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K et al.
Drug Metabolism and Pharmacokinetics, 2022
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.
Hirvensalo P et al.
Clinical and Translational Science, 2022
Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1).
Hussner J et al.
Drug Metabolism and Pharmacokinetics, 2021
Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates.
Medwid S et al.
Frontiers in Pharmacology, 2021
Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers.
Lee SW et al.
The Pharmacogenomics Journal, 2020
Functional Characterization Reveals the Significance of Rare Coding Variations in Human Organic Anion Transporting Polypeptide 2B1 (SLCO2B1).
Yang J et al.
Molecular Pharmaceutics, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA et al.
Journal of Clinical Pharmacology, 2020
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.
Medwid S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2019
Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy.
Chen J et al.
Drug Metabolism and Pharmacokinetics, 2019
Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R et al.
Medical Oncology (northwood, London, England), 2018
Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population.
Cai LL et al.
Scientific Reports, 2017
Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Vanhove T et al.
Clinical Pharmacology and Therapeutics, 2017
Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y et al.
Journal of Pharmaceutical Sciences, 2017
The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers.
Keiser M et al.
Journal of Pharmaceutical Sciences, 2017
The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE et al.
Basic & Clinical Pharmacology & Toxicology, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S et al.
Environmental Toxicology and Pharmacology, 2015
The Regulation of Steroid Action by Sulfation and Desulfation.
Mueller JW et al.
Endocrine Reviews, 2015
Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.
Sato H et al.
Journal of Human Genetics, 2015
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
Meyer zu Schwabedissen HE et al.
Bmc Research Notes, 2014
Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
Kim KA et al.
Journal of Clinical Pharmacology, 2013
SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.
Kim KA et al.
Molecular Biology Reports, 2013
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Shitara Y et al.
Biopharmaceutics & Drug Disposition, 2013
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T et al.
Pharmacogenetics and Genomics, 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
Clarke JD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A et al.
Basic & Clinical Pharmacology & Toxicology, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Triangulation of the human, chimpanzee, and Neanderthal genome sequences identifies potentially compensated mutations.
Zhang G et al.
Human Mutation, 2010
Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2010
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.
Aoki M et al.
Pharmacogenetics and Genomics, 2009
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.
Mougey EB et al.
Pharmacogenetics and Genomics, 2009